Chelsea Therapeutics, Inc. Confirms Plan to File Northera NDA for the Treatment of Neurogenic Orthostatic Hypotension in Third Quarter 2011 and Intent to Pursue Supplemental Falls Claim Following Approval

CHARLOTTE, N.C., April 18, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reaffirms NORTHERA™ (droxidopa) new drug application (NDA) filing strategy following correspondence with the U.S. Food and Drug Administration (FDA) regarding recent data from Northera Study 306A and protocol amendments to ongoing Northera Study 306B comparing the rate of patient reported falls associated with symptomatic neurogenic orthostatic hypotension (NOH) in patients with Parkinson’s disease (PD) taking Northera versus placebo.